Articles tagged "Immunosuppression"

2016 American Transplant Congress
Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.
J. Dickson,¹ W. Vincent III,¹ L. Wu,² J. Thurman,¹ J. Francis,³ M. Nuhn.⁴
¹Pharmacy, Boston Medical Center, Boston, MA; ²Northeastern University, Boston, MA; ³Renal Medicine, Boston Medical Center, Boston, MA; ⁴Transplant Surgery, Boston Medical Center, Boston, MA.
Purpose: Previously, kidney transplant pharmacy services at our institution were limited to medication profile review before and after transplant surgery. Following an OPTN accreditation site…
2016 American Transplant Congress
Conditional Long Term Intestine Patient and Graft Survival Is Improving Under rATG Immunosuppression in Pediatric Intestine Transplantation.
N. Celik,¹ F. Vyas,¹ G. Bond,¹ K. Soltys,¹ J. Rudolph,² R. Sindhi,¹ G. Mazariegos.¹
¹Hillman Center for Pediatric Transplantation, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Intestinal Care and Rehabilitation Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
Aim: We reviewed conditional graft survival and short and long term improvements in children receiving rATG (rabbit anti-thymocyte globulin) immunosuppression for intestine transplantation at a…
2016 American Transplant Congress
Foxp3 Controls Oxidative Phosphorylation in Regulatory T Cells.
U. Beier,¹ A. Angelin,² J. Jiao,¹ H. Xiao,¹ L. Wang,³ S. Dahiya,³ A. Wells,³ D. Wallace,² W. Hancock.³
¹Pediatric Nephrology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; ²Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA; ³Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA.
Current immunosuppressive therapies are limited by non-specificity and toxicities, and new pharmacologic approaches to immunosuppressive therapies are needed. Many T cell subsets have distinct metabolic…
2016 American Transplant Congress
Pre-Transplant IgM to Post-Transplant IgG DSA Conversion May Be Affected by Immunosuppression.
A. Nguyen,¹ M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,² C. Morgan,² A. Maldonado,² P. Terasaki.¹
¹Terasaki Foundation Laboratory, Los Angeles, CA; ²East Carolina University, Greenville, NC.
Post-transplant (tx) IgG donor-specific antibodies (DSA), but not IgM DSA has been identified as one of the major causes of late graft loss. Considering the…
2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…
2016 American Transplant Congress
Impact of Immunosuppressants on Inducing Regulatory T Cells in Human Allo-Immune Responses.
Y. Tanaka, H. Ohdan.
Transplant Surgery, Hiroshima University, Hiroshima, Japan.
A better understanding of cytokine signaling pathways involving transcription factors of the STAT family in T cells responding to allostimulation will improve interpretation of immune-regulatory…
2016 American Transplant Congress
Kidney Transplant Patient Preferences and Trade-Offs for Outcomes After Transplantation.
M. Howell,^1,2 G. Wong,^1,2,3 J. Rose,⁴ A. Tong,^1,2 J. Craig,^1,2 K. Howard.²
¹Centre for Kidney Research, The Childrens Hospital at Westmead, Westmead, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia; ⁴Institute of Choice, University of South Australia, North Sydney, NSW, Australia.
Aim: To evaluate preferences and trade-offs patients may accept to avoid adverse outcomes of long-term immunosuppression. Background: Patient preferences in clinical decisions are increasingly relevant,…
2016 American Transplant Congress
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3
¹Graduate Institute of Clinical Pharmacy, National Taiwan University, College of Medicine, Taipei, Taiwan; ²Surgery, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect…
2016 American Transplant Congress
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
J. Clark,¹ T. Sparkes,¹ B. Masters,¹ J. LaMattina,² R. Barth,² M. Moss.¹
¹University of Maryland Medical Center, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD.
Background: Available literature supports basiliximab induction for safe delay of CNI initiation and renal recovery; however there is a paucity of evidence for use in…
2016 American Transplant Congress
Don't Judge a Book by Its Cover: Normal Liver Enzymes After Transplantation Can Be Associated with Pathologies Requiring Intervention.
C. Sanchez,¹ S. Kumer,² S. Olson,¹ R. Gilroy,¹ T. Schmitt,² B. Kane,² R. Taylor.¹
¹Hepatology/Transplant, University of Kansas, Kansas City, KS; ²Surgery, University of Kansas, Kansas City, KS.
Background:Liver biopsies are employed post-transplant generally to evaluate abnormal liver enzymes (LE); however they are not without risk. Whether post-transplant protocol biopsies (PB) serve any…